Proteonomix, Inc.
OTC: PROT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Moshe Cohen
- Employees
- 164
- Headquarters
- Hawthorne, United States
- IPO year
- 1997
- Market cap
- $791.0
- Website
- https://www.proteonomix.com
Loading PROT…
Loading profile data…Frequently asked questions about PROT
What does Proteonomix, Inc. (PROT) do?
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company’s products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two...
Where does PROT trade?
Proteonomix, Inc. (PROT) trades on the Other OTC.
What sector is PROT in?
Proteonomix, Inc. (PROT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Proteonomix, Inc.?
Michael Moshe Cohen is the chief executive officer of Proteonomix, Inc. (PROT).
Where is Proteonomix, Inc. headquartered?
Proteonomix, Inc. is headquartered in United States.
Does PROT pay a dividend?
Proteonomix, Inc. (PROT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PROT go public?
Proteonomix, Inc. (PROT) completed its initial public offering in 1997.